Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Accounts Payables: 2020-2024

Historic Accounts Payables for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $4.0 million.

  • Janux Therapeutics' Accounts Payables rose 37.90% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 37.90%. This contributed to the annual value of $4.0 million for FY2024, which is 66.09% up from last year.
  • According to the latest figures from FY2024, Janux Therapeutics' Accounts Payables is $4.0 million, which was up 66.09% from $2.4 million recorded in FY2023.
  • Janux Therapeutics' 5-year Accounts Payables high stood at $4.0 million for FY2024, and its period low was $428,000 during FY2020.
  • Its 3-year average for Accounts Payables is $2.9 million, with a median of $2.4 million in 2023.
  • As far as peak fluctuations go, Janux Therapeutics' Accounts Payables surged by 474.30% in 2021, and later declined by 12.16% in 2022.
  • Yearly analysis of 5 years shows Janux Therapeutics' Accounts Payables stood at $428,000 in 2020, then skyrocketed by 474.30% to $2.5 million in 2021, then fell by 12.16% to $2.2 million in 2022, then grew by 12.27% to $2.4 million in 2023, then surged by 66.09% to $4.0 million in 2024.